Resumen

ENRIQUEZ-ACEVES, Isabel et al. Standard Treatment with Bevacizumab as Targeted Therapy in Cervical Cancer. Rev. invest. clín. [online]. 2020, vol.72, n.4, pp.213-218.  Epub 04-Abr-2021. ISSN 2564-8896.  https://doi.org/10.24875/ric.20000061.

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient’s quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

Palabras llave : Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic.

        · texto en Inglés     · Inglés ( pdf )